What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial

Background— Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes. Methods and Results— We evaluated 4162 patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial (acute coronary syndrome patients randomized to pravastatin 40 mg versus atorvastatin 80 mg). The average follow-up BP (systolic and diastolic) was categorized into 10-mm Hg increments. The primary outcome was a composite of death due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal myocardial infarction, or revascularization. The relationship between BP (systolic or diastolic) followed a J- or U-shaped curve association with primary, secondary, and individual outcomes, with increased events rates at both low and high BP values, both unadjusted and after adjustment for baseline variables, baseline C-reactive protein, and on-treatment average levels of low-density lipoprotein cholesterol. A nonlinear Cox proportional hazards model showed a nadir of 136/85 mm Hg (range 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic) at which the incidence of primary outcome was lowest. The curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg. Conclusions— After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially <110/70 mm Hg) may be dangerous. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00382460.

[1]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[2]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[3]  J. Staessen,et al.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.

[4]  M. I. Perez,et al.  Treatment blood pressure targets for hypertension. , 2009, The Cochrane database of systematic reviews.

[5]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[6]  J. Filipovský,et al.  Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease , 2007, Hypertension.

[7]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[8]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[9]  R. D'Agostino,et al.  A likely explanation for the J-curve of blood pressure cardiovascular risk. , 2004, The American journal of cardiology.

[10]  Morris J. Brown,et al.  British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary , 2004, BMJ : British Medical Journal.

[11]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[12]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[13]  J. Whitworth,et al.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.

[14]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[15]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[16]  E. Braunwald,et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.

[17]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[18]  N. Kaplan J-curve not burned off by HOT study , 1998, The Lancet.

[19]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[20]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[21]  J. Staessen Potential adverse effects of blood pressure lowering—J-curve revisited , 1996, The Lancet.

[22]  M. Weinberger Do no harm. Antihypertensive therapy and the 'J' curve. , 1992, Archives of internal medicine.

[23]  R. D'Agostino,et al.  Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. , 1991, BMJ.

[24]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[25]  P. Waller,et al.  Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? , 1988, Journal of human hypertension.

[26]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[27]  J. Lanke,et al.  Both high and low blood pressures risk indicators of death in middle-aged males. Isotonic regression of blood pressure on age applied to data from a 13-year prospective study. , 2009, Acta medica Scandinavica.

[28]  UNTREATED MILD HYPERTENSION A Report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension , 1982, The Lancet.

[29]  I. Stewart RELATION OF REDUCTION IN PRESSURE TO FIRST MYOCARDIAL INFARCTION IN PATIENTS RECEIVING TREATMENT FOR SEVERE HYPERTENSION , 1979, The Lancet.

[30]  T. Anderson RE-EXAMINATION OF SOME OF THE FRAMINGHAM BLOOD-PRESSURE DATA , 1978, The Lancet.